No profile data available.
MindWalk Holdings Corp. (HYFT) is a healthcare company in the medication development research industry, based in Austin, United States, with about 74 full-time employees.
It reported revenue of 15.56 million CAD for fiscal year 2026, down 36.5% from fiscal year 2025, and net income of -13.95 million CAD. In Q1 2027 (the quarter ended July 31, 2026) revenue was 3.83 million CAD, up 21.3% from a year before. Its largest business segment, Project Revenue, brought in 100% of segment revenue in fiscal year 2026; UNITED STATES was the largest region with 66%. Its market capitalization was $70.43 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended April 30, 2026; market data as of October 9, 2026.
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025.
MindWalk Holdings reported 15.56 million CAD in revenue for fiscal year 2026, down 36.5% from 24.52 million CAD in fiscal year 2025. In Q1 2027 revenue was 3.83 million CAD.
Project Revenue, with 15.41 million CAD or 100% of segment revenue in fiscal year 2026. Next: Product Sales (under 1%).
UNITED STATES: 66% of revenue by region in fiscal year 2026, followed by Europe (18%).
$70.43 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include C4 Therapeutics, Inc. (CCCC), Molecular Partners AG (MOLN), Insight Molecular Diagnostics Inc. (IMDX), Caribou Biosciences, Inc. (CRBU).